Biogen has highlighted the growing role of felzartamab in its pipeline during a virtual investor seminar, spotlighting three ...

Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA pre-targeted radioimmunotherapy for relapsed non-Hodgkin lymphoma. Y-mAbs Therapeutics, Inc. announced that the first patient has ...

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market. A couple of months ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Y-mAbs Therapeutics, Inc. announced the presentation of preclinical ...

The poster titled “Preclinical and translational pharmacokinetic (PK) modeling of the self-assembling and disassembling (SADA) bispecific fusion protein CD38-SADA for first-in-human (FIH ...

ISB 2001 was designed to simultaneously target multiple myeloma by binding to the tumor- associated antigens BCMA and CD38, even when expressed at low levels, while engaging T cells to ...

The poster titled “Preclinical and translational pharmacokinetic (PK) modeling of the self-assembling and disassembling (SADA) bispecific fusion protein CD38-SADA for first-in-human (FIH) pretargeted ...